Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
03:42pm, Wednesday, 04'th Jan 2023
Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
02:44pm, Friday, 23'rd Dec 2022 Zacks Investment Research
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
11:17am, Friday, 23'rd Dec 2022
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
The Bunny Portfolio Has Averaged 13.6% Per Year
10:56am, Monday, 12'th Dec 2022
What do you call a stock that has a great earnings growth history, yet sells for modest price?
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
07:30pm, Wednesday, 07'th Dec 2022 Benzinga
RBC Capital Markets initiated coverage on Bio-Rad Laboratories Inc (NYSE: BIO) with an Outperform rating and a $565 price target.
The analyst writes that Bio-Rad has evolved as a public company ov
These Are the Five Best and Worst Performing Healthcare Stocks in October 2022
08:02pm, Monday, 28'th Nov 2022
The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
05:01pm, Friday, 28'th Oct 2022 Zacks Investment Research
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
02:18pm, Friday, 28'th Oct 2022
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Bio-Rad Laboratories, Inc. (BIO) Q3 2022 Earnings Call Transcript
10:23pm, Thursday, 27'th Oct 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Sc
Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
09:45pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
03:31pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
04:01pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decl
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
08:30am, Monday, 17'th Oct 2022
HERCULES, Calif.
Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year?
08:00am, Wednesday, 12'th Oct 2022
Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
12:29pm, Tuesday, 11'th Oct 2022 Benzinga
Reuters
US-China Chip War: KLA Relaxes Chip Supply To China
U.S. chipmaker KLA Corp's (NASDAQ: KLAC) legal department emailed China informing that it shall stop sales and service to "advanced f
